全文获取类型
收费全文 | 511篇 |
免费 | 33篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 25篇 |
妇产科学 | 5篇 |
基础医学 | 58篇 |
口腔科学 | 8篇 |
临床医学 | 69篇 |
内科学 | 169篇 |
皮肤病学 | 20篇 |
神经病学 | 14篇 |
特种医学 | 58篇 |
外科学 | 17篇 |
综合类 | 13篇 |
预防医学 | 7篇 |
眼科学 | 9篇 |
药学 | 27篇 |
中国医学 | 2篇 |
肿瘤学 | 73篇 |
出版年
2022年 | 4篇 |
2021年 | 1篇 |
2020年 | 5篇 |
2019年 | 2篇 |
2018年 | 6篇 |
2017年 | 3篇 |
2016年 | 8篇 |
2015年 | 6篇 |
2014年 | 8篇 |
2013年 | 12篇 |
2012年 | 19篇 |
2011年 | 13篇 |
2010年 | 12篇 |
2009年 | 30篇 |
2008年 | 18篇 |
2007年 | 40篇 |
2006年 | 17篇 |
2005年 | 16篇 |
2004年 | 22篇 |
2003年 | 16篇 |
2002年 | 13篇 |
2001年 | 22篇 |
2000年 | 6篇 |
1999年 | 12篇 |
1998年 | 22篇 |
1997年 | 23篇 |
1996年 | 33篇 |
1995年 | 17篇 |
1994年 | 24篇 |
1993年 | 11篇 |
1992年 | 13篇 |
1991年 | 18篇 |
1990年 | 12篇 |
1989年 | 16篇 |
1988年 | 12篇 |
1987年 | 10篇 |
1986年 | 9篇 |
1985年 | 6篇 |
1984年 | 8篇 |
1982年 | 4篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1977年 | 12篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有576条查询结果,搜索用时 0 毫秒
61.
Organophosphate insecticides, such as Vapona, Naled, and Rabon, are highly potent inhibitors of an enzyme found in human monocytes. The enzyme, a specific monocyte esterase, could be inhibited by Vapona in blood samples via airborne contamination at levels easily achieved from commercial slow-release insecticide strips. Fifty percent inhibition (I50)--as measured on the Hemalog D (Technicon Corp.)--occurred at solution concentrations of 0.22, 1.5, and 2.6 X 10(-6) g/liter for Vapona, Rabon, and Naled, respectively. Parathion (a thiophosphate) and Baygon (a carbamate) were less potent, with I50 values of 3.7 X 10(-5) and 1.5 X 10(-4) g/liter, respectively. Dursban (another thiophosphate) and Carbaryl (a carbamate) showed only marginal inhibition. Eserine, malathion, nicotine and pyrethrum had no inhibitory effect up to 0.5 g/liter. The occurrence of this effect in vivo has not yet been shown, nor is it clear what the implications of such an effect would be. The inhibition of this enzyme by airborne contaminants, however, may interfere with the proper functioning of the Hemalog D. 相似文献
62.
van Agthoven M Faber LM Uyl-de Groot CA Sonneveld P Verdonck LF Willemze R Kluin-Nelemans JC Löwenberg B Huijgens PC 《European journal of haematology》2002,69(4):213-220
Many cost analyses of stem-cell transplantations are available, which is in sharp contrast to the level of cost analyses on first-line chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). Given the scarcity of cost analyses of first-line chemotherapy for NHL, it is difficult to assess the economic impact of upcoming new treatment modalities. Therefore we performed an analysis on costs of diagnosis and treatment of patients with newly diagnosed NHL who were treated with standard CHOP (-like) chemotherapy. As many NHL patients are treated in trials and the economic effects of the trial participation are unknown, our analysis included both patients treated according to trial protocols and patients treated according to standard local practice (SLP). The cost analysis was based on the total medical consumption of the patients. It was found that costs of the trial and SLP groups are within comparable ranges, although costs of diagnostic tests were somewhat higher within the trials. In elderly patients, SLP chemotherapy was discontinued more frequently in case of leucocytopenia or thrombocytopenia. This analysis provides basic information about the costs of first-line standard chemotherapy for patients with newly diagnosed aggressive NHL and the plausible ranges in which these costs may vary. Given the results, we will initiate larger studies to investigate whether trial treatments (showing more or less similar costs as SLP treatments) are more cost-effective for patients with aggressive NHL. 相似文献
63.
64.
M B van't Veer J C Kluin-Nelemans C E van der Schoot W L van Putten H J Adriaansen E R van Wering 《British journal of haematology》1992,80(4):458-465
In order to standardize and assess the quality of immunophenotyping of leukaemias and lymphomas for diagnostic purposes, a cooperative study group in the Netherlands, SIHON, has formulated guidelines for the composition of antibody panels to be applied and guidelines for the interpretation of the marker analysis. To assess the value of these guidelines frozen cell samples of three patients with different haematological malignancies were sent to the 26 participating laboratories twice a year. Here we present the results with respect to the marker analysis and to the immunological diagnosis on 387 samples from 18 patients. A large inter-laboratory variation was seen in the percentage of positive cells for each marker, which influenced the valuation of a marker to be discordant positive in up to 23% and discordant negative in up to 40%. No single major factor could be traced to explain the large variation in the results. However, probably due to the balanced composition of the antibody panel and to the application of the guidelines for interpretation, this variation did not much influence the agreement in immunological diagnosis. In only 13/387 samples (3.3%) differences in the percentage of positive cells caused disagreement in the final diagnosis. In 23 samples (5.9%) the disagreement was due to an incorrect application of the guidelines. Quantitative data of single observations obtained from different laboratories, in which the materials and methods are not standardized, cannot be compared; but standardization of guidelines for marker sets and for interpretation contributes to a high grade of agreement in immunological diagnosis. 相似文献
65.
Moser EC Kluin-Nelemans HC Carde P Meerwaldt JH Tirelli U Aleman BM Baars J Thomas J van Glabbeke M Noordijk EM 《International journal of radiation oncology, biology, physics》2006,66(4):1168-1177
PURPOSE: Whether salvage therapy in patients with advanced aggressive non-Hodgkin's lymphoma (NHL) in partial remission (PR) should consist of radiotherapy or autologous stem-cell transplantation (ASCT) is debatable. We evaluated the impact of radiotherapy on outcome in PR patients treated in four successive European Organization for Research and Treatment of Cancer trials for aggressive NHL. PATIENTS AND METHODS: Records of 974 patients (1980-1999) were reviewed regarding initial response, final outcome, and type and timing of salvage treatment. After 8 cycles of doxorubicin-based chemotherapy, 227 NHL patients were in PR and treated: 114 received involved field radiotherapy, 16 ASCT, 93 second-line chemotherapy, and 4 were operated. Overall survival (OS) and progression-free survival (PFS) after radiotherapy were estimated (Kaplan-Meier method) and compared with other treatments (log-rank). Impact on survival was evaluated by multivariate analysis (Cox proportional hazards model). RESULTS: The median PFS in PR patients was 4.2 years and 48% remained progression-free at 5 years. Half of the PR patients converted to a complete remission. After conversion, survival was comparable to patients directly in complete remission. Radiotherapy resulted in better OS and PFS compared with other treatments, especially in patients with low to intermediate International Prognostic Index score, bulky disease, or nodal disease only. Correction by multivariate analysis for prognostic factors such as stage, bulky disease, and number of extranodal locations showed that radiotherapy was clearly the most significant factor affecting both OS and PFS. CONCLUSION: This retrospective analysis demonstrates that radiotherapy can be effective for patients in PR after fully dosed chemotherapy; assessment in a randomized trial (radiotherapy vs. ASCT) is justified. 相似文献
66.
Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z 《Human reproduction (Oxford, England)》1997,12(11):2359-2365
Certain patients have a tendency for high response to gonadotrophin therapy
which is often not ameliorated with prior gonadotrophin- releasing hormone
agonist (GnRHa) suppression. As a result, these patients are frequently
cancelled and often experience ovarian hyperstimulation syndrome (OHSS)
episodes during in-vitro fertilization (IVF)-embryo transfer cycles.
Patients with polycystic ovarian syndrome (PCOS) have been noted to be
particularly sensitive to exogenous gonadotrophin therapy. We have
developed a protocol which is effective in improving IVF outcome in high
responder patients, including those with PCOS. Oral contraceptive pills
(OCP) are taken for 25 days followed by s.c. leuprolide acetate, 1 mg/day,
which is overlapped with the final 5 days of oral contraceptive
administration. Low-dose gonadotrophin stimulation is then initiated on the
third day of withdrawal bleeding in the form of either human menopausal
gonadotrophins or purified urinary follicle-stimulating hormone at a dosage
of 150 IU/day. Over a 5 year period, we reviewed our experience utilizing
this dual method of suppression in 99 cycles obtained in 73 high responder
patients. There were only 13 cancellations prior to embryo transfer
(13.1%). The clinical and ongoing pregnancy rates per initiated cycle were
46.5 and 40.4% respectively. Only eight patients experienced mild-moderate
OHSS following treatment. For those patients who had undergone previous
IVF-embryo transfer cycles at our centre, significant improvements were
noted in oocyte fertilization rates, embryo implantation rates and
clinical/ongoing pregnancy rates with this protocol. Hormonal analyses
revealed that the chief mechanism may be through an improved luteinizing
hormone/follicle-stimulating hormone ratio following dual suppression. An
additional feature of this dual method of suppression is significantly
lower serum androgen concentrations, particularly dehydroepiandrosterone
sulphate.
相似文献
67.
In the present study we demonstrate that Aza-dC in combination with Amsacrine has major antileukaemic properties in patients who have not already received extensive Ara-C therapy. Eight out of 11 patients in their first relapse of acute leukaemia achieved complete remission. Cross resistance between Ara-C and Aza-dC was revealed by the lack of antileukaemic activity in five patients with with Ara-C resistant leukaemia. Combination therapy with Aza-dC/Ams-acrine induced a considerable period of a granulocytopenia (28-35 days), while the toxic effect on erythro- and megakaryopoiesis was comparable to that reported for high dose Ara-C/Amsacrine chemotherapy. Remarkable is the long disappearance time for leukaemic blast cells in bone marrow, i.e. 3-5 weeks in some cases. Analysis of cell membrane markers showed a loss of the early differentiation antigens CD34 and CD33 from leukaemic bone marrow cells after 7 days of Aza-dC treatment, which is suggestive of leukaemic cell differentiation. In the small group of patients tested for DNA hypomethylation no association existed between the degree of hypomethylation and clinical response. Non-haematologic side effects were considerable in patients receiving the highest dosages of Aza-dC and consisted of severe, although usually reversible, gastrointestinal and neurological complications. In comparison with Ara-C, Aza-dC causes less nausea and vomiting and is therefore better tolerated. 相似文献
68.
Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol 总被引:2,自引:0,他引:2
69.
70.
We report on headache induced by a somatostatin octapeptide analog (octreotide) used for the treatment of acromegaly, This "rebound" headache has severe tension-type characteristics and occurs every 6–8 h. It resolves dramatically within minutes with octreotide administration. This is the first report of headache developing under treatment with octreotide. 相似文献